MCID: VRL003
MIFTS: 52

Variola Major

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Variola Major

MalaCards integrated aliases for Variola Major:

Name: Variola Major 12 15 74
Smallpox 74

Classifications:



External Ids:

Disease Ontology 12 DOID:0050508
ICD9CM 36 050.0
SNOMED-CT 69 47452006

Summaries for Variola Major

Disease Ontology : 12 A smallpox that results in severe infection, located in skin, has material basis in Variola virus. The infection results in_formation_of lesions.

MalaCards based summary : Variola Major, also known as smallpox, is related to smallpox and variola minor, and has symptoms including fever, pruritus and exanthema. An important gene associated with Variola Major is TLR3 (Toll Like Receptor 3), and among its related pathways/superpathways are Akt Signaling and IL-2 Pathway. The drugs Vaccines and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include skin, skin and testes, and related phenotypes are neoplasm and respiratory system

Wikipedia : 77 Smallpox was an infectious disease caused by one of two virus variants, Variola major and Variola minor.... more...

Related Diseases for Variola Major

Diseases related to Variola Major via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 96)
# Related Disease Score Top Affiliating Genes
1 smallpox 32.5 IFNG IL2
2 variola minor 11.6
3 hand, foot and mouth disease 10.2 IFNG TLR3
4 campylobacteriosis 10.2 IFNG TLR4
5 vaccinia 10.2
6 myositis fibrosa 10.2 IFNG TLR4
7 hepatitis e 10.1 IFNG TLR3
8 allergic conjunctivitis 10.1 IFNG TLR3
9 invasive aspergillosis 10.1 IFNG TLR4
10 aspergillosis 10.1 IFNG TLR4
11 q fever 10.1 IFNG TLR4
12 dengue hemorrhagic fever 10.1 IFNG TLR3
13 echinococcosis 10.1 IFNG TLR4
14 orofacial granulomatosis 10.1 CCL3 IFNG
15 melioidosis 10.1 IFNG TLR4
16 typhoid fever 10.1 IFNG TLR4
17 boutonneuse fever 10.1 IL2 TLR4
18 salmonellosis 10.1 IFNG TLR4
19 fixed drug eruption 10.1 IFNG IL2
20 berylliosis 10.1 IFNG IL2
21 atopic keratoconjunctivitis 10.1 IFNG IL2
22 keratoconjunctivitis 10.1 IFNG IL2
23 conjunctivitis 10.1 IFNG IL2
24 cutaneous leishmaniasis 10.1 IFNG TLR4
25 clonorchiasis 10.1 IFNG IL2
26 crohn's colitis 10.1 IFNG IL2
27 chronic active epstein-barr virus infection 10.1 IFNG IL2
28 intermediate uveitis 10.1 IFNG IL2
29 lymphadenitis 10.1 IFNG TLR4
30 posterior uveitis 10.0 IFNG IL2
31 erythema multiforme 10.0 IFNG IL2
32 coccidiosis 10.0 IFNG IL2
33 hematopoietic stem cell transplantation 10.0 IFNG IL2
34 vernal conjunctivitis 10.0 IFNG IL2
35 stevens-johnson syndrome/toxic epidermal necrolysis 10.0 IFNG IL2
36 autoimmune disease of endocrine system 10.0 IFNG IL2
37 chlamydia 10.0 IFNG TLR4
38 hypersensitivity reaction type iv disease 10.0 IFNG IL2
39 leprosy 3 10.0 IFNG IL2
40 acute graft versus host disease 10.0 IFNG IL2
41 lepromatous leprosy 10.0 IFNG IL2
42 toxoplasmosis 10.0 IFNG TLR4
43 autoimmune uveitis 10.0 IFNG IL2
44 testicular disease 10.0 IFNG IL2
45 pleurisy 10.0 IFNG IL2
46 herpes zoster 10.0 IFNG IL2
47 tropical spastic paraparesis 10.0 IFNG IL2
48 cowpox 10.0
49 tonsillitis 10.0 IFNG IL2
50 mumps 10.0 IFNG IL2

Graphical network of the top 20 diseases related to Variola Major:



Diseases related to Variola Major

Symptoms & Phenotypes for Variola Major

UMLS symptoms related to Variola Major:


fever, pruritus, exanthema

MGI Mouse Phenotypes related to Variola Major:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.26 IFNG IL2 TLR3 TLR4
2 respiratory system MP:0005388 8.92 IFNG IL2 TLR3 TLR4

Drugs & Therapeutics for Variola Major

Drugs for Variola Major (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 35)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
2 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
3 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
4 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2,Phase 1
5 gamma-Globulins Phase 4,Phase 3,Phase 2,Phase 1
6 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2,Phase 1
7 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
8 Iron-Dextran Complex Phase 3
9
Phenol Approved, Experimental Phase 2 108-95-2 996
10
Benzocaine Approved, Investigational Phase 1, Phase 2 94-09-7, 1994-09-7 2337
11
tannic acid Approved Phase 1, Phase 2 1401-55-4
12 Immunoglobulin G Phase 2,Phase 1
13
Mannitol Approved, Investigational Phase 1 69-65-8 453 6251
14 Pharmaceutical Solutions Phase 1
15 Natriuretic Agents Phase 1
16 diuretics Phase 1
17 Anti-Infective Agents Phase 1
18 Adjuvants, Immunologic Phase 1
19 interferons Phase 1
20 polysaccharide-K Phase 1
21 Interferon Inducers Phase 1
22 Anti-Bacterial Agents Phase 1
23 Antiviral Agents Phase 1
24 Antibiotics, Antitubercular Phase 1
25 Radiation-Protective Agents Phase 1
26 Protective Agents Phase 1
27 Keyhole-limpet hemocyanin Phase 1
28 Liver Extracts Phase 1
29 Carboxymethylcellulose Sodium Phase 1
30 Poly I-C Phase 1
31 Cathartics Phase 1
32 Gastrointestinal Agents Phase 1
33 Poly ICLC Phase 1
34 Laxatives Phase 1
35 Interferon-gamma

Interventional clinical trials:

(show top 50) (show all 85)
# Name Status NCT ID Phase Drugs
1 VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV Recruiting NCT02443623 Phase 4
2 Special Access Program IMVAMUNE® Completed NCT03472014 Phase 4
3 Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers Completed NCT01317238 Phase 3 smallpox vaccine CJ-50300
4 Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers Completed NCT01056770 Phase 3 smallpox vaccine CJ-50300
5 Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial Not yet recruiting NCT03699124 Phase 3
6 A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects Completed NCT01144637 Phase 3
7 Safety and Efficacy of CJ-50300 in Healthy Volunteers Completed NCT00607243 Phase 2, Phase 3
8 IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo Recruiting NCT02977715 Phase 3
9 A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000® Active, not recruiting NCT01913353 Phase 3
10 A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat Completed NCT02474589 Phase 3 tecovirimat
11 VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV Completed NCT01158157 Phase 3
12 Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers Unknown status NCT00103584 Phase 1, Phase 2
13 Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection Completed NCT02038881 Phase 2
14 Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination Completed NCT00053495 Phase 2
15 Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults Completed NCT00053482 Phase 2
16 Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine Completed NCT00466245 Phase 2 MVA Smallpox vaccine;Placebo
17 Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults Completed NCT00258947 Phase 2
18 Dressing Preparations for Smallpox Completed NCT00063856 Phase 1, Phase 2
19 Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination Terminated NCT00053508 Phase 2
20 APSV in Vaccinia Naive Adults Completed NCT00050518 Phase 2
21 A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects Completed NCT01668537 Phase 2
22 A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults Completed NCT00026611 Phase 2
23 A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects Completed NCT00857493 Phase 2
24 Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine. Completed NCT00189956 Phase 2
25 Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE® Completed NCT01827371 Phase 2
26 A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects Completed NCT00316524 Phase 2
27 MVA Post-Event: Administration Timing and Boost Study Completed NCT00437021 Phase 1, Phase 2 Placebo (subcutaneous);Placebo (scarification)
28 Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally Completed NCT00914732 Phase 2
29 Expanded Dryvax Dilution Study in Previously Vaccinated Adults Completed NCT00050505 Phase 2
30 ACAM 3000 MVA at Harvard Medical School Completed NCT00133575 Phase 1, Phase 2
31 High Dose IMVAMUNE® in Vaccinia-Naive Individuals Completed NCT00879762 Phase 2 Placebo
32 Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients Completed NCT00316589 Phase 2
33 A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis Completed NCT00316602 Phase 2
34 Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients Completed NCT00189904 Phase 1, Phase 2
35 Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT Completed NCT00038987 Phase 1, Phase 2
36 Dryvax Dilution-Prev Vacc Adults Completed NCT00032708 Phase 2
37 An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees Completed NCT00686582 Phase 2
38 Evaluation and Treatment of Eye Complications of Vaccinia Vaccination Completed NCT00081835 Phase 2 NP-016 Vaccine Immune Globulin (IV-VIG)
39 Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis Completed NCT00723489 Phase 1, Phase 2 YFV-17D Placebo
40 A Study to Assess the Effectiveness of a New Malaria Vaccine Candidate by Infecting Vaccinated Volunteers With Malaria Parasites Completed NCT00890760 Phase 1, Phase 2
41 PSA-Based Vaccine and Radiotherapy to Treat Localized Prostate Cancer Completed NCT00005916 Phase 2 rV-PSA;rF-PSA;rV-B7.1
42 Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246 Completed NCT00907803 Phase 2 ST-246 400 mg;ST-246 600 mg;Placebo
43 EMaBS TB Vaccine Study Not yet recruiting NCT03681860 Phase 1, Phase 2
44 Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults Completed NCT00079820 Phase 1
45 Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive Terminated NCT00282581 Phase 1
46 Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD) Withdrawn NCT00389103 Phase 1
47 Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax® Completed NCT00042094 Phase 1
48 Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects Completed NCT00189969 Phase 1
49 Human Immune Responses Smallpox Completed NCT00068198 Phase 1
50 Safety and Immunogenicity of CJ-50300 Completed NCT00336635 Phase 1

Search NIH Clinical Center for Variola Major

Genetic Tests for Variola Major

Anatomical Context for Variola Major

The Foundational Model of Anatomy Ontology organs/tissues related to Variola Major:

20
Skin

MalaCards organs/tissues related to Variola Major:

42
Skin, Testes, T Cells, Eye, Kidney, Bone, Placenta

Publications for Variola Major

Articles related to Variola Major:

(show top 50) (show all 2346)
# Title Authors Year
1
Atypical Cowpox Virus Infection in Smallpox-Vaccinated Patient, France. ( 30666929 )
2019
2
Recurrent epicardial ventricular tachycardia following smallpox vaccination. ( 30693196 )
2019
3
Assessing a drug for an eradicated human disease: US Food and Drug Administration review of tecovirimat for the treatment of smallpox. ( 30853252 )
2019
4
Monkeypox - Enhancing public health preparedness for an emerging lethal human zoonotic epidemic threat in the wake of the smallpox post-eradication era. ( 30453097 )
2018
5
Beyond the myths: Novel findings for old paradigms in the history of the smallpox vaccine. ( 30048524 )
2018
6
An antiviral for smallpox. ( 30082865 )
2018
7
Smallpox Autoinoculation Via Tattoo in a Soldier. ( 30085282 )
2018
8
Bayesian Phylogeography and Pathogenic Characterization of Smallpox Based on HA, ATI, and CrmB Genes. ( 30099520 )
2018
9
The spectre of smallpox lingers. ( 30104592 )
2018
10
First Smallpox Drug Approved. ( 30140861 )
2018
11
Smallpox antiviral ends decades-long search. ( 30188546 )
2018
12
Drug Approved to Treat Smallpox After a Bioterrorist Attack. ( 30358593 )
2018
13
Long-term effects of smallpox vaccination on expression of the HIV-1 co-receptor CCR5 in women. ( 30440008 )
2018
14
Oral Tecovirimat for the Treatment of Smallpox. ( 30462945 )
2018
15
Design of inhibitors of thymidylate kinase from Variola virus as new selective drugs against smallpox - Part II. ( 30488769 )
2018
16
The last case of smallpox. ( 30507458 )
2018
17
Generalized Vaccinia After Smallpox Vaccination With Concomitant Primary Epstein Barr Virus Infection. ( 30766264 )
2017
18
Use of the LC16m8 Smallpox Vaccine in Immunocompromised Individuals Is Still Too Risky. ( 25921466 )
2015
19
Reply to "Use of the LC16m8 Smallpox Vaccine in Immunocompromised Individuals Is Still Too Risky". ( 25921467 )
2015
20
Game theory of pre-emptive vaccination before bioterrorism or accidental release of smallpox. ( 25926701 )
2015
21
Smallpox vaccine, ACAM2000: Sites and duration of viral shedding and effect of povidone iodine on scarification site shedding and immune response. ( 25930115 )
2015
22
Smallpox: 12,000 years from plagues to eradication: a dermatologic ailment shaping the face of society. ( 25970158 )
2015
23
Risks Associated With Smallpox Vaccination in Pregnancy: A Systematic Review and Meta-analysis. ( 26000516 )
2015
24
The rediscovery of smallpox. ( 24438205 )
2014
25
Smallpox vaccination, colonial Sydney and serendipity. ( 24641158 )
2014
26
Smallpox and globalization or the first achieved plannetary goal. ( 24697019 )
2014
27
The smallpox threat: a time to reconsider global policy. ( 24712454 )
2014
28
Human antibody responses to the polyclonal Dryvax vaccine for smallpox prevention can be distinguished from responses to the monoclonal replacement vaccine ACAM2000. ( 24759651 )
2014
29
Infectious diseases: Smallpox watch. ( 24784198 )
2014
30
Are we there yet? The smallpox research agenda using variola virus. ( 24789223 )
2014
31
Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humans. ( 23254433 )
2013
32
Remaining questions about clinical variola major. ( 21470458 )
2011
33
Studies of the suitability of fowlpox as a decontamination and thermal stability simulant for variola major. ( 20148078 )
2009
34
Differentiation of Variola major and Variola minor variants by MGB-Eclipse probe melt curves and genotyping analysis. ( 19345728 )
2009
35
Coadministration of cidofovir and smallpox vaccine reduced vaccination side effects but interfered with vaccine-elicited immune responses and immunity to monkeypox. ( 19004937 )
2009
36
Gender effects on humoral immune responses to smallpox vaccine. ( 19200827 )
2009
37
Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens. ( 17950773 )
2008
38
Structure-assisted discovery of Variola major H1 phosphatase inhibitors. ( 17505108 )
2007
39
Infectiousness of smallpox relative to disease age: estimates based on transmission network and incubation period. ( 17156499 )
2007
40
Characterization and use of mammalian-expressed vaccinia virus extracellular membrane proteins for quantification of the humoral immune response to smallpox vaccines. ( 17596428 )
2007
41
US military smallpox vaccination program: occupational impact of immunizations on aircrew in Air Mobility Command, US Air Force. ( 18178764 )
2007
42
Overproduction, purification, and biochemical characterization of the dual specificity H1 protein phosphatase encoded by variola major virus. ( 16793284 )
2006
43
Optimal bandaging of smallpox vaccination sites to decrease the potential for secondary vaccinia transmission without impairing lesion healing. ( 17080375 )
2006
44
Standardization of a neutralizing anti-vaccinia antibodies titration method: an essential step for titration of vaccinia immunoglobulins and smallpox vaccines evaluation. ( 15572006 )
2005
45
Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. ( 15623576 )
2005
46
Photophobia following smallpox vaccination. ( 15629350 )
2005
47
Cautious interpretation of data regarding myopericarditis associated with smallpox vaccination. ( 15629393 )
2005
48
Live smallpox experiments may go ahead. ( 15645545 )
2005
49
Severe headaches following smallpox vaccination. ( 15663622 )
2005
50
Smallpox vaccines: from first to second to third generation. ( 15680437 )
2005

Variations for Variola Major

Expression for Variola Major

Search GEO for disease gene expression data for Variola Major.

Pathways for Variola Major

Pathways related to Variola Major according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.11 CCL3 IL2 TLR3 TLR4
2
Show member pathways
12.88 IFNG IL2 TLR3 TLR4
3
Show member pathways
12.5 IFNG TLR3 TLR4
4
Show member pathways
12.43 IL2 TLR3 TLR4
5
Show member pathways
12.38 CCL3 IFNG IL2 TLR3 TLR4
6
Show member pathways
12.31 IFNG IL2 TLR4
7 12.27 IFNG IL2 TLR3
8
Show member pathways
12.22 IFNG IL2 TLR3 TLR4
9
Show member pathways
12.03 IFNG TLR3 TLR4
10
Show member pathways
11.92 IFNG TLR3 TLR4
11 11.89 IFNG TLR3 TLR4
12
Show member pathways
11.82 CCL3 IFNG IL2
13
Show member pathways
11.75 IL2 TLR3 TLR4
14 11.71 IFNG IL2 TLR4
15
Show member pathways
11.63 CCL3 IFNG IL2
16 11.6 TLR3 TLR4
17 11.58 IFNG IL2
18
Show member pathways
11.55 IFNG IL2
19 11.53 IFNG IL2
20 11.5 CCL3 IFNG TLR4
21 11.47 IFNG IL2
22
Show member pathways
11.45 IFNG IL2
23
Show member pathways
11.43 IFNG IL2
24 11.43 CCL3 IFNG TLR4
25 11.34 IFNG IL2
26 11.34 CCL3 IFNG IL2
27 11.31 IFNG TLR4
28 11.3 IFNG IL2
29 11.29 IFNG TLR4
30 11.27 IFNG IL2
31 11.18 CCL3 IFNG IL2
32 11.09 IFNG IL2
33
Show member pathways
11.04 IFNG IL2 TLR3 TLR4
34 11.03 IFNG IL2
35 10.99 IFNG IL2
36 10.95 IFNG IL2
37 10.9 TLR3 TLR4

GO Terms for Variola Major

Cellular components related to Variola Major according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intracellular GO:0005622 8.8 CCL3 TLR3 TLR4

Biological processes related to Variola Major according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.83 CCL3 IFNG IL2
2 inflammatory response GO:0006954 9.81 CCL3 TLR3 TLR4
3 immune response GO:0006955 9.78 CCL3 IFNG IL2 TLR4
4 positive regulation of gene expression GO:0010628 9.71 CCL3 IFNG TLR3 TLR4
5 positive regulation of JNK cascade GO:0046330 9.67 TLR3 TLR4
6 cellular response to mechanical stimulus GO:0071260 9.66 TLR3 TLR4
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.66 IFNG IL2
8 apoptotic signaling pathway GO:0097190 9.65 TLR3 TLR4
9 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.65 TLR3 TLR4
10 positive regulation of interleukin-6 production GO:0032755 9.64 TLR3 TLR4
11 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.64 TLR3 TLR4
12 extrinsic apoptotic signaling pathway GO:0097191 9.63 IFNG TLR3
13 positive regulation of interferon-gamma production GO:0032729 9.62 IL2 TLR4
14 positive regulation of nitric oxide biosynthetic process GO:0045429 9.62 IFNG TLR4
15 positive regulation of B cell proliferation GO:0030890 9.61 IL2 TLR4
16 toll-like receptor signaling pathway GO:0002224 9.61 TLR3 TLR4
17 cellular response to interferon-gamma GO:0071346 9.61 CCL3 TLR3 TLR4
18 lipopolysaccharide-mediated signaling pathway GO:0031663 9.6 CCL3 TLR4
19 positive regulation of interleukin-1 beta secretion GO:0050718 9.59 CCL3 TLR4
20 positive regulation of interleukin-8 production GO:0032757 9.58 TLR3 TLR4
21 positive regulation of interferon-beta production GO:0032728 9.58 TLR3 TLR4
22 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.57 TLR3 TLR4
23 positive regulation of chemokine production GO:0032722 9.56 TLR3 TLR4
24 necroptotic process GO:0070266 9.55 TLR3 TLR4
25 regulation of regulatory T cell differentiation GO:0045589 9.54 IFNG IL2
26 I-kappaB phosphorylation GO:0007252 9.52 TLR3 TLR4
27 negative regulation of interleukin-17 production GO:0032700 9.51 IFNG TLR4
28 positive regulation of tumor necrosis factor production GO:0032760 9.5 CCL3 TLR3 TLR4
29 MyD88-independent toll-like receptor signaling pathway GO:0002756 9.49 TLR3 TLR4
30 positive regulation of interferon-beta biosynthetic process GO:0045359 9.46 TLR3 TLR4
31 negative regulation of MyD88-independent toll-like receptor signaling pathway GO:0034128 9.37 TLR3 TLR4
32 positive regulation of interleukin-12 production GO:0032735 9.33 IFNG TLR3 TLR4
33 regulation of dendritic cell cytokine production GO:0002730 9.26 TLR3 TLR4
34 negative regulation of osteoclast differentiation GO:0045671 9.13 CCL3 TLR3 TLR4
35 positive regulation of inflammatory response GO:0050729 8.92 CCL3 IL2 TLR3 TLR4

Molecular functions related to Variola Major according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.8 CCL3 IFNG IL2

Sources for Variola Major

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....